44
Participants
Start Date
December 22, 2022
Primary Completion Date
December 22, 2026
Study Completion Date
December 22, 2026
Photobiomodulation Therapy
Participants with a history of allo-HCT and diagnosis with oral chronic GvHD randomized to the treatment arm will be treated with oral photobiomodulation/PBM (via Thor LX2.3 system device) for 28 days
Placebo sham device
Participants with a history of allo-HCT and diagnosis with oral chronic GvHD randomized to the placebo arm will be treated with a placebo sham device (via Thor LX2.3 sham device setting) for 28 days
RECRUITING
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
RECRUITING
Memorial Sloan Kettering Westchester (Consent only), Harrison
RECRUITING
Memorial Sloan Kettering Cancer Center @ Nassau (Consent only), Uniondale
RECRUITING
Memorial Sloan Kettering Cancer Center @ Commack (Consent only), Commack
RECRUITING
University of Pittsburgh Medical Center (Data Collection Only), Pittsburgh
RECRUITING
National Institute of Health (Data Collection AND Specimen Analysis), Bethesda
RECRUITING
Memorial Sloan Kettering at Basking Ridge (Consent only), Basking Ridge
RECRUITING
Memorial Sloan Kettering Monmouth (Consent only), Middletown
RECRUITING
Memorial Sloan Kettering Cancer Center @ Bergen (Consent only), Montvale
Memorial Sloan Kettering Cancer Center
OTHER